A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

Completed · Phase 2

Conditions studied: Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma

In brief

This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

Key facts

Study ID

NCT00880360

Run by

The University of Texas Health Science Center at San Antonio

People needed

19

Starts

2007-02-01

Expected to finish

2010-04-01

Last updated by the study team

2018-03-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide informed consent
• Not on Immune modulating drugs
• Life expectancy less than 6 months

You may not qualify if…

• Unable to tolerate phlebotomy
• Germ cell or stromal cell cancers of the ovaries
• Active autoimmune disease

Where it is running

• CTRC at UTHSCSA — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.